Zehua Bian 1 , Jia Zhang 1,2 , Jiwei Zhang 1 , Min Li 1 , Yuyang Feng 1,2 , Xue Wang 2 , Surui Yao 1 , Guoying Jin 1 , Jun Du 3 , Weifeng Han 3 , Yuan Yin 1 , Shenglin Huang 4 , Bojian Fei 3 , Jian Zou 5 , Zhaohui Huang 6,2 . Show Affiliations »
Abstract
Purpose: Long non-coding RNAs (lncRNAs) play key roles in human cancers. Here, FEZF1-AS1, a highly overexpressed lncRNA in colorectal cancer, was identified by lncRNA microarrays. We aimed to explore the roles and possible molecular mechanisms of FEZF1-AS1 in colorectal cancer.Experimental Design: LncRNA expression in colorectal cancer tissues was measured by lncRNA microarray and qRT-PCR. The functional roles of FEZF1-AS1 in colorectal cancer were demonstrated by a series of in vitro and in vivo experiments. RNA pull-down, RNA immunoprecipitation and luciferase analyses were used to demonstrate the potential mechanisms of FEZF1-AS1. Results: We identified a series of differentially expressed lncRNAs in colorectal cancer using lncRNA microarrays, and revealed that FEZF1-AS1 is one of the most overexpressed. Further validation in two expanded colorectal cancer cohorts confirmed the upregulation of FEZF1-AS1 in colorectal cancer, and revealed that increased FEZF1-AS1 expression is associated with poor survival. Functional assays revealed that FEZF1-AS1 promotes colorectal cancer cell proliferation and metastasis. Mechanistically, FEZF1-AS1 could bind and increase the stability of the pyruvate kinase 2 (PKM2) protein, resulting in increased cytoplasmic and nuclear PKM2 levels. Increased cytoplasmic PKM2 promoted pyruvate kinase activity and lactate production (aerobic glycolysis), whereas FEZF1-AS1-induced nuclear PKM2 upregulation further activated STAT3 signaling. In addition, PKM2 was upregulated in colorectal cancer tissues and correlated with FEZF1-AS1 expression and patient survival.Conclusions: Together, these data provide mechanistic insights into the regulation of FEZF1-AS1 on both STAT3 signaling and glycolysis by binding PKM2 and increasing its stability. Clin Cancer Res; 24(19); 4808-19. ©2018 AACR. ©2018 American Association for Cancer Research.
Purpose: Long non-coding RNAs (lncRNAs) play key roles in human cancers . Here, FEZF1 -AS1 , a highly overexpressed lncRNA in colorectal cancer , was identified by lncRNA microarrays. We aimed to explore the roles and possible molecular mechanisms of FEZF1 -AS1 in colorectal cancer .Experimental Design: LncRNA expression in colorectal cancer tissues was measured by lncRNA microarray and qRT-PCR. The functional roles of FEZF1 -AS1 in colorectal cancer were demonstrated by a series of in vitro and in vivo experiments. RNA pull-down, RNA immunoprecipitation and luciferase analyses were used to demonstrate the potential mechanisms of FEZF1 -AS1 . Results: We identified a series of differentially expressed lncRNAs in colorectal cancer using lncRNA microarrays, and revealed that FEZF1 -AS1 is one of the most overexpressed. Further validation in two expanded colorectal cancer cohorts confirmed the upregulation of FEZF1 -AS1 in colorectal cancer , and revealed that increased FEZF1 -AS1 expression is associated with poor survival. Functional assays revealed that FEZF1 -AS1 promotes colorectal cancer cell proliferation and metastasis. Mechanistically, FEZF1 -AS1 could bind and increase the stability of the pyruvate kinase 2 (PKM2 ) protein, resulting in increased cytoplasmic and nuclear PKM2 levels. Increased cytoplasmic PKM2 promoted pyruvate kinase activity and lactate production (aerobic glycolysis), whereas FEZF1 -AS1 -induced nuclear PKM2 upregulation further activated STAT3 signaling. In addition, PKM2 was upregulated in colorectal cancer tissues and correlated with FEZF1 -AS1 expression and patient survival.Conclusions: Together, these data provide mechanistic insights into the regulation of FEZF1 -AS1 on both STAT3 signaling and glycolysis by binding PKM2 and increasing its stability. Clin Cancer Res; 24(19); 4808-19. ©2018 AACR. ©2018 American Association for Cancer Research.
Entities: Chemical
Disease
Gene
Species
Year: 2018
PMID: 29914894 DOI: 10.1158/1078-0432.CCR-17-2967
Source DB: PubMed Journal: Clin Cancer Res ISSN: 1078-0432 Impact factor: 12.531